Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
ConclusionsIn patients ≥ 65 years of age with T2D and mild renal insufficiency with inadequate glycemic control on metformin ± sulfonylurea, treatment with sitagliptin for 24 weeks resulted in improvement in HbA1c relative to treatment with dapagliflozin that is consistent with that previously observed in th e overall population. Both treatments were generally well tolerated.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Clinical Trials | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Januvia